OncoSil Medical Ltd (ASX:OSL) has appointed Michael Warrener as Global Sales and Marketing Director.
Warrener will be responsible for implementing the company’s commercialisation strategy and infrastructure.
He will be based in Sydney and will oversee the initial market launch in Europe, Australia and key Asian markets.
Warrener spent eight years with Sirtex Medical Ltd (ASX:SRX).
Daniel Kenny, managing director, commented:
“As we progress though the regulatory process, we are working in parallel to advance our sales and marketing infrastructure, and Michael’s appointment is a key part of this strategy.
"His relevant and senior level experience in the medical device sector in introducing a new brachytherapy device for cancer and building adoption and reimbursement makes him a key addition to our leadership team.
"I look forward to working with Michael as we pursue our goal to commercialise OncoSil™ as a viable new treatment for pancreatic cancer and other solid tumours."
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.